Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04350190 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Apatinib mesylate tablet
DRUG: PD-1

Sponsor

Wei Jiang

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]